Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:ITRMOTCMKTS:MATNNASDAQ:MYOSNASDAQ:PHIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$2.68+1.9%$4.77$2.35▼$44.80$1.82M0.351.11 million shs117,120 shsITRMIterum Therapeutics$1.69+7.6%$1.51$0.62▼$2.50$25.79M2.36496,807 shs106,274 shsMATNMateon Therapeutics$0.04$0.04$0.13▼$0.38$3.79M1.33338,444 shs22,308 shsMYOSMYOS RENS Technology$3.35$0.74▼$3.85$16.70M1.081.68 million shsN/APHIOPhio Pharmaceuticals$0.68-2.8%$0.80$0.50▼$6.85$3.13M1.44366,014 shs106,030 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+5.82%-37.26%-34.45%-71.96%-89.20%ITRMIterum Therapeutics+1.29%+9.79%+0.64%-8.72%+57.00%MATNMateon Therapeutics+5.56%-9.52%+3.68%-5.00%-9.52%MYOSMYOS RENS Technology0.00%0.00%0.00%-50.36%+431.21%PHIOPhio Pharmaceuticals+5.22%+11.18%-3.29%+28.34%-78.67%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path2.5016 of 5 stars3.55.00.00.02.40.00.6ITRMIterum Therapeutics1.1975 of 5 stars3.53.00.00.00.60.00.6MATNMateon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.1303 of 5 stars3.53.00.00.00.82.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.001,392.54% UpsideITRMIterum Therapeutics3.00Buy$6.00255.03% UpsideMATNMateon TherapeuticsN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00486.51% UpsideCurrent Analyst RatingsLatest BPTH, MYOS, ITRM, MATN, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.002/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AMATNMateon TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AMYOSMYOS RENS Technology$1.03M0.00N/AN/A$0.13 per share0.00PHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)MATNMateon Therapeutics-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/AMYOSMYOS RENS Technology-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/APHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)Latest BPTH, MYOS, ITRM, MATN, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PHIOPhio PharmaceuticalsN/A-$0.17-$0.17-$0.17N/AN/A3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60ITRMIterum Therapeutics3.631.891.89MATNMateon TherapeuticsN/A0.170.17MYOSMYOS RENS Technology0.113.781.94PHIOPhio PharmaceuticalsN/A5.705.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%ITRMIterum Therapeutics9.21%MATNMateon Therapeutics0.07%MYOSMYOS RENS Technology4.97%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%ITRMIterum Therapeutics5.40%MATNMateon Therapeutics39.22%MYOSMYOS RENS Technology45.30%PHIOPhio Pharmaceuticals0.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10680,000658,000OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableMATNMateon Therapeutics1390.24 millionN/ANot OptionableMYOSMYOS RENS Technology1512.19 millionN/ANot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionableBPTH, MYOS, ITRM, MATN, and PHIO HeadlinesSourceHeadlinePhio Pharmaceuticals reports progress on cancer therapy PH-762investing.com - April 24 at 11:06 AMWhy Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?benzinga.com - April 22 at 3:21 PMIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsfinance.yahoo.com - April 22 at 3:21 PMIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsglobenewswire.com - April 22 at 1:10 PMPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)globenewswire.com - April 16 at 7:30 AMPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)globenewswire.com - April 11 at 7:30 AMNational Spotlight Features Phio’s Innovative RNAi Technology Platformfinance.yahoo.com - April 3 at 10:33 AMNational Spotlight Features Phio's Innovative RNAi Technology Platformglobenewswire.com - April 3 at 7:30 AMPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Updateglobenewswire.com - April 2 at 7:30 AMPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - March 21 at 7:52 AMPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Researchglobenewswire.com - March 13 at 2:00 PMPhio Pharmaceuticals Corp PHIOmorningstar.com - March 10 at 7:10 AMAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)markets.businessinsider.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disordersfinance.yahoo.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disordersglobenewswire.com - March 6 at 10:30 AMChallenges and Opportunities for Key Players in the Hypopigmentation Disorder Product Marketopprairie.com - February 23 at 1:35 PMDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030uk.finance.yahoo.com - February 14 at 10:33 AMAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)markets.businessinsider.com - February 6 at 1:30 PMPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - January 31 at 8:14 AMPhio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - January 28 at 12:19 PMRecent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)knoxdaily.com - January 1 at 1:39 PMPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersmsn.com - December 19 at 9:00 PMWhy Phio Pharmaceuticals Stock Is Nosedivingmsn.com - December 7 at 5:55 PMPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceedsfinance.yahoo.com - December 7 at 12:54 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Mateon TherapeuticsOTCMKTS:MATNMateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.MYOS RENS TechnologyNASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.